Responses
Ovarian cancer
2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.